News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Women's Health, Inc. (TEVA) to Present New Data at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists


5/6/2013 9:19:09 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Teva Women’s Health, a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced new data for the oral contraceptives (OC) QuartetteTM (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets and an investigational 28-day OC regimen (150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days, followed by 7 days of 10 mcg EE) will be featured at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists (ACOG). The meeting, held in New Orleans from May 4 – 8, 2013 features three company-sponsored posters.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES